Nanocarrier based approaches for targeting breast cancer stem cells

References

• Ferlay J, Héry C, Autier P, Sankaranarayanan R. Global Burden of Breast Cancer. Breast cancer epidemiology. New York, NY: Springer; 2010. p. 1–19.
   Google Scholar
• Sandhu GS, Erqou S, Patterson H, et al. Prevalence of triple-negative breast cancer in India: systematic review and meta-analysis. J Glob Oncol. 2016;2:412–421.
   PubMedGoogle Scholar
• Dontu G, Al‐Hajj M, Abdallah WM, et al. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;36:59–72.
   PubMed Web of Science ®Google Scholar
• Wicha M, Dontu G, Al-Hajj M, et al. Stem cells in normal breast development and breast cancer. Breast Cancer Res. 2003;5:50.
   Google Scholar
• Chen K, Huang Y-H, Chen J-L. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34:732–740.
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–3988.
   PubMed Web of Science ®Google Scholar
• Britton K, Eyre R, Harvey I, et al. Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 2012;323:97–105.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111.
   PubMed Web of Science ®Google Scholar
• Li R-J, Ying X, Zhang Y, et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release. 2011;149:281–291.
   PubMed Web of Science ®Google Scholar
• Sabe H. Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor β signalling. J Biochem. 2011;149:633–639.
   PubMed Web of Science ®Google Scholar
• Hu C, Niestroj M, Yuan D, Chang S, Chen J. Treating cancer stem cells and cancer metastasis using glucose-coated gold nanoparticles. Int J Nanomed. 2015;10:2065.
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–563.
   PubMed Web of Science ®Google Scholar
• Liu Z, Bandyopadhyay A, Nichols RW, et al. Blockade of autocrine TGF-β signaling inhibits stem cell phenotype, survival, and metastasis of murine breast cancer cells. J Stem Cell Res Ther. 2012;2:1.
   PubMedGoogle Scholar
• Chapellier M, Maguer-Satta V. BMP2, a key to uncover luminal breast cancer origin linked to pollutant effects on epithelial stem cells niche. Mol Cell Oncol. 2016;3:e1026527.
   PubMed Web of Science ®Google Scholar
• Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer. 2012;48:2104–2116.
   PubMed Web of Science ®Google Scholar
• Borah A, Raveendran S, Rochani A, et al. Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy. Oncogenesis. 2015;4:e177.
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond). 2012;7:597–615.
   PubMed Web of Science ®Google Scholar
• Gao J, Feng S-S, Guo Y. Nanomedicine for treatment of cancer stem cells. Nanomedicine (Lond). 2014;9:181–184.
   PubMedGoogle Scholar
• Muntimadugu E, Kumar R, Saladi S, et al. CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf B Biointerfaces. 2016;143:532–546.
   PubMed Web of Science ®Google Scholar
• Mamaeva V, Niemi R, Beck M, et al. Inhibiting notch activity in breast cancer stem cells by glucose functionalized nanoparticles carrying γ-secretase inhibitors. Mol Ther. 2016;24:926–936.
   PubMed Web of Science ®Google Scholar
• Sun M, Yang C, Zheng J, et al. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Acta Biomater. 2015;28:171–182.
   PubMed Web of Science ®Google Scholar
• Goodarzi N, Amini M, Ghahremani MH, et al. Hyaluronic acid-drug conjugate of docetaxel and metformin to target cancer cells and cancer stem cells: synthesis and characterization. J Control Release. 2013;1:e59.
   Google Scholar
• Zhou X, Chen L, Nie W, et al. Dual-responsive mesoporous silica nanoparticles mediated codelivery of doxorubicin and Bcl-2 SiRNA for targeted treatment of breast cancer. J Phys Chem C. 2016;120:22375–22387.
   Web of Science ®Google Scholar
• Tummala S, Kumar MS, Pindiprolu SK. Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles. Drug Deliv. 2016;23:3505–3519.
   PubMed Web of Science ®Google Scholar
• Talluri SV, Kuppusamy G, Karri VVSR, et al. Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45:474–488.
   PubMed Web of Science ®Google Scholar
• Siddhartha VT, Pindiprolu SKSS, Chintamaneni PK, et al. RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies. Artif Cells Nanomed Biotechnol. 2017;1–11. doi: 10.1080/21691401.2017.1313267. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Talluri S, Pindiprolu S, Janarthanam R, Kuppusamy G. Development and efficacy evaluation of smart nanocarriers for targeting breast cancers. Eur J Cancer. 2016;57:S122.
   Web of Science ®Google Scholar
• Bazak R, Houri M, El Achy S, et al. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141:769–784.
   PubMed Web of Science ®Google Scholar
• Shi F, Yang F, He X, et al. Inhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells. J Drug Target. 2016;24:34–46.
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23:605–618.
   PubMed Web of Science ®Google Scholar
• Wang D, Huang J, Wang X, et al. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials. 2013;34:7662–7673.
   PubMed Web of Science ®Google Scholar
• Goodarzi N, Ghahremani MH, Amini M, et al. CD44-targeted docetaxel conjugate for cancer cells and cancer stem-like cells: a novel hyaluronic acid-based drug delivery system. Chem Biol Drug Des. 2014;83:741–752.
   PubMed Web of Science ®Google Scholar
• Rao W, Wang H, Han J, et al. Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano. 2015;9:5725–5740.
   PubMed Web of Science ®Google Scholar
• Swaminathan SK, Roger E, Toti U, et al. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release. 2013;171:280–287.
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Salmasi Z, Hashemi M, et al. Single-walled carbon nanotubes functionalized with aptamer and piperazine–polyethylenimine derivative for targeted siRNA delivery into breast cancer cells. Int J Pharm. 2015;485:50–60.
   PubMed Web of Science ®Google Scholar
• Alibolandi M, Ramezani M, Sadeghi F, et al. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro. Int J Pharm. 2015;479:241–251.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Kanwar JR, kumar Athalya P, et al. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. J Biomed Sci. 2015;22:4.
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344.
   PubMedGoogle Scholar
• Fleming HE, Janzen V, Celso CL, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. 2008;2:274–283.
   PubMed Web of Science ®Google Scholar
• Choi H, Chun Y-S, Kim T-Y, et al. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res. 2010;70:10101–10111.
   PubMed Web of Science ®Google Scholar
• Huang J, Tao C, Yu Y, et al. Simultaneous targeting of differentiated breast cancer cells and breast cancer stem cells by combination of docetaxel-and sulforaphane-loaded self-assembled poly (D, L-lactide-co-glycolide)/hyaluronic acid block copolymer-based nanoparticles. J Biomed Nanotechnol. 2016;12:1463–1477.
   PubMed Web of Science ®Google Scholar
• Zhao P, Dong S, Bhattacharyya J, et al. iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors. Mol Pharm. 2014;11:2703–2712.
   PubMed Web of Science ®Google Scholar
• Zhao P, Xia G, Dong S, et al. An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors. Biomaterials. 2016;93:1–9.
   PubMed Web of Science ®Google Scholar
• Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776.
   PubMed Web of Science ®Google Scholar
• Androutsellis-Theotokis A, Leker RR, Soldner F, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442:823–826.
   PubMed Web of Science ®Google Scholar
• Schweisguth F. Regulation of notch signaling activity. Curr Biol. 2004;14:R129–R138.
   PubMed Web of Science ®Google Scholar
• Yang H, Li Y, Li T, et al. Multifunctional core/shell nanoparticles cross-linked polyetherimide-folic acid as efficient Notch-1 siRNA carrier for targeted killing of breast cancer. Sci Rep. 2014;4:7072.
   PubMed Web of Science ®Google Scholar
• Moses H, Barcellos-Hoff MH. TGF-beta biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol. 2011;3:a003277.
   PubMed Web of Science ®Google Scholar
• Zuo Z-Q, Chen K-G, Yu X-Y, et al. Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition. Biomaterials. 2016;82:48–59.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen C, Qian P, et al. Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nat Commun. 2015;6:5988.
   Web of Science ®Google Scholar
• Svärd J, Henricson KH, Persson-Lek M, et al. Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev Cell. 2006;10:187–197.
   PubMed Web of Science ®Google Scholar
• Hu K, Zhou H, Liu Y, et al. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells. Nanoscale. 2015;7:8607–8618.
   PubMed Web of Science ®Google Scholar
• You J, Zhao J, Wen X, et al. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles. J Control Release. 2015;202:40–48.
   PubMed Web of Science ®Google Scholar
• Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13:211–217.
   PubMed Web of Science ®Google Scholar
• Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995;11:69–74.
   PubMed Web of Science ®Google Scholar
• Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci. 1994;19:222–227.
   PubMed Web of Science ®Google Scholar
• Stahl N, Farruggella TJ, Boulton TG, et al. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science. 1995;267:1349.
   PubMed Web of Science ®Google Scholar
• Heim MH, Kerr IM, Stark GR, et al. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science. 1995;267:1347
   PubMed Web of Science ®Google Scholar
• Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. Anticancer Res. 2015;35:39–46.
   PubMed Web of Science ®Google Scholar
• Kim S-Y, Kang JW, Song X, et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal. 2013;25:961–969.
   PubMed Web of Science ®Google Scholar
• Misra SK, Jensen TW, Pan D. Enriched inhibition of cancer and stem-like cancer cells via STAT-3 modulating niclocelles. Nanoscale. 2015;7:7127–7132.
   PubMed Web of Science ®Google Scholar
• Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005;5:231–237.
   PubMed Web of Science ®Google Scholar
• Martinou J-C, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011;21:92–101.
   PubMed Web of Science ®Google Scholar
• Chen AM, Zhang M, Wei D, et al. Co‐delivery of doxorubicin and Bcl‐2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug‐resistant cancer cells. Small. 2009;5:2673–2677.
   PubMed Web of Science ®Google Scholar
• Li S-Y, Sun R, Wang H-X, et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J Control Release. 2015;205:7–14.
   PubMed Web of Science ®Google Scholar
• Shen S, Du X-J, Liu J, et al. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy. J Control Release. 2015;208:14–24.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu W-L, Guo J, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release. 2008;129:18–25.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yao H-J, Yu Y, et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials. 2012;33:565–582.
   PubMed Web of Science ®Google Scholar
• Sadhukha T, Niu L, Wiedmann TS, et al. Effective elimination of cancer stem cells by magnetic hyperthermia. Mol Pharm. 2013;10:1432–1441.
   PubMed Web of Science ®Google Scholar
• Shervington A, Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 2008;26:535–542.
   PubMed Web of Science ®Google Scholar
• Yin L, Castagnino P, Assoian RK. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res. 2008;68:800–807.
   PubMed Web of Science ®Google Scholar
• Rabindran SK, He H, Singh M, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 1998;58:5850–5858.
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Ross DD, Doyle LA, et al. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000;60:47–50.
   PubMed Web of Science ®Google Scholar
• Woehlecke H, Osada H, Herrmann A, et al. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int J Cancer. 2003;107:721–728.
   PubMed Web of Science ®Google Scholar
• Zhao S, Smith KS, Deveau AM, et al. Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines. J Med Chem. 2002;45:1559–1562.
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 2004;64:1242–1246.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Brynskikh AM, et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release. 2010;143:290–301.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Li Y, et al. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res. 2004;21:2226–2233.
   PubMed Web of Science ®Google Scholar
• Danson S, Ferry D, Alakhov V, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004;90:2085–2091.
   PubMed Web of Science ®Google Scholar
• Minko T, Batrakova EV, Li S, et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release. 2005;105:269–278.
   PubMed Web of Science ®Google Scholar
• Venne A, Li S, Mandeville R, et al. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 1996;56:3626–3629.
   PubMed Web of Science ®Google Scholar
• Wang H, Agarwal P, Zhao S, et al. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials. 2015;72:74–89.
   PubMed Web of Science ®Google Scholar
• Misra R, Das M, Sahoo BS, et al. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation. Int J Pharm. 2014;475:372–384.
   PubMed Web of Science ®Google Scholar
• Dong C, Yuan T, Wu Y, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013;23:316–331.
   PubMed Web of Science ®Google Scholar
• Ginestier C, Monville F, Wicinski J, et al. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells. 2012;30:1327–1337.
   PubMed Web of Science ®Google Scholar
• Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24:213–228.
   PubMed Web of Science ®Google Scholar
• Salani B, Del Rio A, Marini C, et al. Metformin, cancer and glucose metabolism. Endocr Relat Cancer. 2014;21:R461–R471.
   PubMed Web of Science ®Google Scholar
• Xu Q, Zhu T, Yi C, et al. Characterization and evaluation of metformin-loaded solid lipid nanoparticles for cellular and mitochondrial uptake. Drug Dev Ind Pharm. 2016;42:701–706.
   PubMed Web of Science ®Google Scholar
• Jain K, Paranandi KS, Sridharan S, et al. Autophagy in breast cancer and its implications for therapy. Am J Cancer Res. 2013;3:251–265.
   PubMed Web of Science ®Google Scholar
• Mai TT, Moon J, Song Y, et al. Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells. Cancer Lett. 2012;321:144–153.
   PubMed Web of Science ®Google Scholar
• Singh BN, Kumar D, Shankar S, et al. Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells. Biochem Pharmacol. 2012;84:1154–1163.
   PubMed Web of Science ®Google Scholar
• Sun R, Shen S, Zhang Y-J, et al. Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells. Biomaterials. 2016;103:44–55.
   PubMed Web of Science ®Google Scholar
• Bozorgi A, Khazaei M, Khazaei MR. New findings on breast cancer stem cells: a review. J Breast Cancer. 2015;18:303–312.
   PubMed Web of Science ®Google Scholar
• He L, Gu J, Lim LY, et al. Nanomedicine-mediated therapies to target breast cancer stem cells. Front Pharmacol. 2016;7:313.
   PubMed Web of Science ®Google Scholar
• Culig Z. Cytokine disbalance in common human cancers. Biochim Biophys Acta. 2011;1813:308–314.
   PubMed Web of Science ®Google Scholar
• Korkaya H, Kim G-i, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47:570–584.
   PubMed Web of Science ®Google Scholar
• Kanapathipillai M, Brock A, Ingber DE. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv Drug Deliv Rev. 2014;79:107–118.
   PubMed Web of Science ®Google Scholar
• Kanapathipillai M, Mammoto A, Mammoto T, et al. Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix. Nano Lett. 2012;12:3213–3217.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Skitzki J, Stoolman L, et al. Intratumoral IL-12 and TNF-α-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol. 2004;11:147–156.
   PubMed Web of Science ®Google Scholar
• Knop K, Hoogenboom R, Fischer D, et al. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed. 2010;49:6288–6308.
   PubMed Web of Science ®Google Scholar
• Maeda H, Kabanov A, Kataoka K, Okano T. Polymer drugs in the clinical stage: advantages and prospects. New York: Springer; 2006.
   Google Scholar
• Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol. 2004;83:97–111.
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991
   PubMed Web of Science ®Google Scholar
• Kale AA, Torchilin VP. Environment-responsive multifunctional liposomes. In: Weissig V, editor. Liposomes: methods and protocols, volume 1: pharmaceutical nanocarriers. New York: Springer; 2010; p. 213–242.
   Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–1626.
   PubMed Web of Science ®Google Scholar
• Kaur S, Mehra NK, Jain K, et al. Development and evaluation of targeting ligand-anchored CNTs as prospective targeted drug delivery system. Artif Cells Nanomedicine Biotechnol. 2017;45:242–250.
   PubMed Web of Science ®Google Scholar
• Xia P. Surface markers of cancer stem cells in solid tumors. Curr Stem Cell Res Ther. 2014;9:102–111.
   PubMed Web of Science ®Google Scholar
• Hamad I, Hunter A, Szebeni J, et al. Poly (ethylene glycol) s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol. 2008;46:225–232.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9:57.
   PubMed Web of Science ®Google Scholar
• Deng X, Wu X, Weng H, Song F. The siRNA-mediated silencing of Bmi-1 promotes apoptosis and inhibits invasion of MCF-7 breast cancer cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi [Chin J Cell Mol Immunol.]. 2016;32:1036.
   PubMedGoogle Scholar
• Zakerzadeh E, Alizadeh E, Samadi Kafil H, et al. Novel antibacterial polymeric nanocomposite for smart co-delivery of anticancer drugs. Artif Cells Nanomed Biotechnol. 2016;1–12. doi: 10.1080/21691401.2016.1260576. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Yu M, Han S, Kou Z, et al. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance. Artif Cells Nanomed Biotechnol. 2017;1–10. doi: 10.1080/21691401.2017.1307215. [Epub ahead of print]
   Web of Science ®Google Scholar
• Godsey ME, Suryaprakash S, Leong KW. Materials innovation for co-delivery of diverse therapeutic cargos. RSC Adv. 2013;3:24794–24811.
   PubMed Web of Science ®Google Scholar
• Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10:R10.
   PubMed Web of Science ®Google Scholar
• Klonisch T, Wiechec E, Hombach-Klonisch S, et al. Cancer stem cell markers in common cancers–therapeutic implications. Trends Mol Med. 2008;14:450–460.
   PubMed Web of Science ®Google Scholar
• Bostad M, Olsen CE, Peng Q, et al. Light-controlled endosomal escape of the novel CD133-targeting immunotoxin AC133-saporin by photochemical internalization − a minimally invasive cancer stem cell-targeting strategy. J Control Release. 2015;206:37–48.
   PubMed Web of Science ®Google Scholar
• Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004;64:5818–5824.
   PubMed Web of Science ®Google Scholar
• Gilboa-Geffen A, Hamar P, Le MT, et al. Gene knockdown by EpCAM aptamer–siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells. Mol Cancer Ther. 2015;14:2279–2291.
   PubMed Web of Science ®Google Scholar
• Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci. 2012;109:11717–11722.
   PubMed Web of Science ®Google Scholar
• Jang G-B, Hong I-S, Kim R-J, et al. WNT/β-Catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res. 2015;75:1691–1702.
   PubMed Web of Science ®Google Scholar
• Takebe N, Harris PJ, Warren RQ, et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011;8:97–106.
   PubMed Web of Science ®Google Scholar
• Chen B, Dodge ME, Tang W, et al. Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5:100–107.
   PubMed Web of Science ®Google Scholar
• Grudzien P, Lo S, Albain KS, et al. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res. 2010;30:3853–3867.
   PubMed Web of Science ®Google Scholar
• Epenetos A, Kousparou C, Stylianou S. Inhibition of Notch signaling for the treatment of human carcinomas. AACR Annual Meeting, April 18–22, 2009; Denver, CO.
   Google Scholar
• Hoey T, Yen W-C, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009;5:168–177.
   PubMed Web of Science ®Google Scholar
• Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444:1032–1037.
   PubMed Web of Science ®Google Scholar
• Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444:1083–1087.
   PubMed Web of Science ®Google Scholar
• Scehnet JS, Jiang W, Kumar SR, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 2007;109:4753–4760.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang W, Tang W, et al. Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells. Tumor Biol. 2016;37:1919–1931.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Masuelli L, De Smaele E, et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget. 2016;7:9250.
   PubMed Web of Science ®Google Scholar
• Thakur R, Trivedi R, Rastogi N, et al. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep. 2015;5:10194.
   PubMed Web of Science ®Google Scholar
• Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7:e1000121.
   PubMed Web of Science ®Google Scholar
• Lai Y, Yu X, Lin X, et al. Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt. Int J Mol Med. 2016;37:369–377.
   PubMed Web of Science ®Google Scholar
• Lima RT, Martins LM, Guimaraes JE, et al. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 2004;11:309–316.
   PubMed Web of Science ®Google Scholar
• Pandey PR, Okuda H, Watabe M, et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat. 2011;130:387–398.
   PubMed Web of Science ®Google Scholar
• Londoño-Joshi AI, Oliver PG, Li Y, et al. Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. Breast Cancer Res Treat. 2012;133:437–445.
   PubMed Web of Science ®Google Scholar
• Gong C, Bauvy C, Tonelli G, et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene. 2013;32:2261–2272.
   PubMed Web of Science ®Google Scholar
• Marini C, Salani B, Massollo M, et al. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle. 2013;12:3490–3499.
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507–7511.
   PubMed Web of Science ®Google Scholar
• Zhao F, Ming J, Zhou Y, et al. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemother Pharmacol. 2016;77:963–972.
   PubMed Web of Science ®Google Scholar
• Zhang H, Lu H, Xiang L, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci USA. 2015;112:E6215–E6223.
   PubMed Web of Science ®Google Scholar
• Samanta D, Gilkes DM, Chaturvedi P, et al. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci USA. 2014;111:E5429–E5438.
   Web of Science ®Google Scholar
• Lock F, McDonald P, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32:5210–5219.
   PubMed Web of Science ®Google Scholar
• Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010;120:485–497.
   PubMed Web of Science ®Google Scholar
• Yip N, Fombon I, Liu P, et al. Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011;104:1564–1574.
   PubMed Web of Science ®Google Scholar
• Hou Z-J, Luo X, Zhang W, et al. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget. 2015;6:6326.
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, et al. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat. 2011;126:355–364.
   PubMed Web of Science ®Google Scholar
• Pan J-X, Ding K, Wang C-Y. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer. 2012;31:178.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang H, Wang X, et al. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials. 2012;33:679–691.
   PubMed Web of Science ®Google Scholar
• Ke X-Y, Ng VWL, Gao S-J, et al. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials. 2014;35:1096–1108.
   PubMed Web of Science ®Google Scholar
• Prud'homme GJ, Glinka Y, Toulina A, et al. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One. 2010;5:e13831.
   PubMed Web of Science ®Google Scholar
• Chen D, Pamu S, Cui Q, et al. Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem. 2012;20:3031–3037.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang X, Liu Y, et al. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumor Biol. 2012;33:1349–1362.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang T, Korkaya H, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res. 2010;16:2580–2590.
   PubMed Web of Science ®Google Scholar
• Gener P, Gouveia LP, Sabat GR, et al. Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine Nanotechnol Biol Med. 2015;11:1883–1892.
   PubMed Web of Science ®Google Scholar
• Ren X, Liu L, Zhou Y, et al. Nanoparticle siRNA against BMI-1 with a polyethylenimine–laminarin conjugate for gene therapy in human breast cancer. Bioconj Chem. 2015;27:66–73.
   PubMed Web of Science ®Google Scholar